丙型肝炎治療市場：依藥物類別、給藥途徑、通路及地區分類

Hepatitis C Drugs Market, By Drug Class, By Route of Administration, By Distribution Channel, By Geography

出版日期: 2026年04月28日 | 出版商:

Coherent Market Insights | 英文 250+ Pages | 商品交期: 2-3個工作天內

價格

簡介目錄

預計到 2026 年，C型肝炎治療市場規模將達到 103 億美元，到 2033 年將達到 140.2 億美元。預計從 2026 年到 2033 年，該市場將以 4.5% 的複合年成長率成長。

報告範圍		報告詳情
基準年：	2025	2026年市場規模：	103億美元
歷史數據時期：	2020-2024	預測期：	2026-2033
2026年至2033年預測期間的複合年成長率：	4.50%	2033年市場規模預測：	140.2億美元

丙型肝炎是一種肝臟感染疾病，可導致嚴重的肝損傷。它是由C型肝炎病毒引起。美國約有240萬人患有此病。然而，由於該疾病通常症狀輕微或無症狀，許多人對此毫不知情。病毒透過感染者的血液和體液傳播。

丙型肝炎的階段：潛伏期。這是指從最初接觸病毒到出現症狀的時間。潛伏期可能為14至80天，平均為45天。急性丙型肝炎。這是一種短期疾病，通常在病毒進入人體後的前六個月內出現。之後，有些感染者體內的病毒會被自然清除。慢性丙型肝炎。在大多數C型肝炎感染者（高達85%）中，病情會發展到長期階段（超過六個月）。這被稱為“慢性丙型肝炎”，並可能導致嚴重的健康問題，例如肝癌和肝硬化。肝硬化。這種疾病會導致炎症，隨著時間的推移，健康的肝細胞會被瘢痕組織取代。這個過程通常需要20到30年，但如果您飲酒或感染了愛滋病毒，病情可能會進展得更快。

市場動態

全球丙型肝炎盛行率的上升預計將在預測期內推動市場成長。例如，根據美國國家生物技術資訊中心（NCBI）於2021年9月18日發布的數據，印度丙型肝炎病毒（HCV）的盛行率為0.5%，約有470萬至1,090萬人受到影響。

北美洲
- 美國
- 加拿大
歐洲
- 英國
- 德國
- 法國
- 義大利
- 西班牙
- 俄羅斯
- 其他歐洲國家
亞太地區
- 中國
- 日本
- 印度
- 澳洲
- ASEAN
- 韓國
- 其他亞太國家
拉丁美洲
- 巴西
- 墨西哥
- 阿根廷
- 其他拉丁美洲國家
中東
- GCC
- 以色列
- 其他中東國家
非洲
- 南非
- 北非
- 中非

第8章競爭情勢

Gilead Sciences
AbbVie
Merck & Co
Bristol-Myers Squibb
Johnson & Johnson
Hoffmann-La Roche AG
Boehringer Ingelheim
Achillion Pharmaceuticals

第9章

調查方法
關於本公司

簡介目錄

Product Code: CMI1489

Hepatitis C Drugs Market is estimated to be valued at USD 10.30 Bn in 2026 and is expected to reach USD 14.02 Bn by 2033, growing at a compound annual growth rate (CAGR) of 4.5% from 2026 to 2033.

Report Coverage		Report Details
Base Year:	2025	Market Size in 2026:	USD 10.30 Bn
Historical Data for:	2020 To 2024	Forecast Period:	2026 To 2033
Forecast Period 2026 to 2033 CAGR:	4.50%	2033 Value Projection:	USD 14.02 Bn

Hepatitis C is a liver infection that can lead to serious liver damage. It's caused by the hepatitis C virus. About 2.4 million people in the U.S. have the disease. But it causes few symptoms, so most of them don't know. The virus spreads through an infected person's blood or body fluids.

Stages of Hepatitis C: Incubation period. This is the time between first exposures to the start of the disease. It can last anywhere from 14 to 80 days, but the average is 45. Acute hepatitis C. This is a short-term illness that lasts for the first 6 months after the virus enters your body. After that, some people who have it will get rid of, or clear, the virus on their own. Chronic hepatitis C. For most people who get hepatitis C - up to 85% - the illness moves into a long-lasting stage (longer than 6 months). This is called a chronic hepatitis C infection and can lead to serious health problems like liver cancer or cirrhosis. Cirrhosis. This disease leads to inflammation that, over time, replaces your healthy liver cells with scar tissue. It usually takes about 20 to 30 years for this to happen, though it can be faster if you drink alcohol or have HIV.

Market Dynamics:

The increasing prevalence of hepatitis C globally is expected to aid in the market growth over the forecast period. For instance, according to the data published by the National Center for Biotechnology Information on September 18, 2021, the prevalence rate of HCV in India is 0.5%, affecting about 4.7 to 10.9 million people.

Hepatitis C Drugs Market Segmentation:

By Drug Class (Revenue, USD Bn, 2021 - 2033)
NS3/4A Protease Inhibitors
NS5A Inhibitors
NS5B Polymerase Inhibitors
Combination Drugs
Others
By Route of Administration (Revenue, USD Bn, 2021 - 2033)
Oral Drugs
Intravenous
Others
By Distribution Channel (Revenue, USD Bn, 2021 - 2033)
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
Regional Insights (Revenue, USD Bn, 2021 - 2033)
North America
- U.S.
- Canada
Latin America
- Brazil
- Argentina
- Mexico
- Rest of Latin America
Europe
- Germany
- U.K.
- Spain
- France
- Italy
- Russia
- Rest of Europe
Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
Middle East
- GCC Countries
- Israel
- Rest of Middle East
Africa
- South Africa
- North Africa
- Central Africa
Top Companies in Hepatitis C Drugs Market:
Gilead Sciences
AbbVie
Merck & Co
Bristol-Myers Squibb
Johnson & Johnson
Hoffmann-La Roche AG
Boehringer Ingelheim
Achillion Pharmaceuticals

1. Research Objectives and Assumptions

Research Objectives
Assumptions
Abbreviations

2. Market Purview

Report Description
- Market Definition and Scope
Executive Summary
- Market Snippet, By Drug Class
- Market Snippet, By Route of Administration
- Market Snippet, By Distribution Channel
- Market Snippet, By Region
Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

Market Dynamics
- Drivers
  - Growing Prevalence of Hepatitis C Globally
  - Increasing Government Initiatives
- Restraints
  - Increasing Adverse Effects
- Opportunities
  - Increasing Product Availability in Various Regions
Impact Analysis
Key Highlights
Regulatory Scenario
Product launch/Approvals
PEST Analysis
PORTER's Analysis
Merger and Acquisition Scenario

4. Hepatitis C Drugs Market, By Drug Class, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2026 and 2033 (%)
- Y-o-Y Growth Analysis, 2022 - 2033
- Segment Trends
NS3/4A Protease Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
NS5A Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
NS5B Polymerase Inhibitors
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Combination Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Bn)

5. Hepatitis C Drugs Market, By Route of Administration, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Oral Drugs
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Intravenous
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)

6. Hepatitis C Drugs Market, By Distribution Channel, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, 2023and 2033 (%)
- Y-o-Y Growth Analysis, 2022- 2033
- Segment Trends
Hospital Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Retail Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)
Online Pharmacies
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2021 - 2033, (US$ Billion)

7. Hepatitis C Drugs Market, By Region, 2021 - 2033, (US$ Bn)

Introduction
- Market Share Analysis, By Country, 2023and 2033 (%)
- Y-o-Y Growth Analysis, For Country 2022-2033
- Country Trends
North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - U.S.
  - Canada
Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - U.K.
  - Germany
  - France
  - Italy
  - Spain
  - Russia
  - Rest of Europe
Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - China
  - Japan
  - India
  - Australia
  - ASEAN
  - South Korea
  - Rest of Asia Pacific
Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - Brazil
  - Mexico
  - Argentina
  - Rest of Latin America
Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - GCC
  - Israel
  - Rest of Middle East
Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Route of Administration, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2021 - 2033, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 - 2033, (US$ Bn)
  - South Africa
  - North Africa
  - Central Africa

8. Competitive Landscape

Gilead Sciences
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
AbbVie
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Merck & Co
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Bristol-Myers Squibb
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Johnson & Johnson
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Hoffmann-La Roche AG
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Boehringer Ingelheim
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Achillion Pharmaceuticals
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
Analyst Views